GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
EA005212B1
(ru)
|
1999-12-24 |
2004-12-30 |
Авентис Фарма Лимитед |
Азаиндолы
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
WO2002016348A1
(fr)
*
|
2000-08-09 |
2002-02-28 |
Astrazeneca Ab |
Derives bicycliques antiangiogeniques
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
EP1698627A1
(fr)
*
|
2000-09-15 |
2006-09-06 |
Vertex Pharmaceuticals Incorporated |
Composés de pyrazole comme inhibiteurs de la protéine kinase
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
JP4105949B2
(ja)
|
2000-09-15 |
2008-06-25 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼインヒビターとして有用なピラゾール化合物
|
ZA200301703B
(en)
*
|
2000-09-15 |
2004-03-02 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors.
|
PT1355905E
(pt)
*
|
2000-12-21 |
2007-05-31 |
Vertex Pharma |
Compostos de pirazole úteis como inibidores de proteínaquinase
|
AU2006201228B2
(en)
*
|
2000-12-21 |
2010-01-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole Compounds Useful as Protein Kinase Inhibitors
|
ES2324981T3
(es)
|
2000-12-21 |
2009-08-21 |
Smithkline Beecham Corporation |
Pirimidinaminas como moduladores de la angiogenesis.
|
US6756374B2
(en)
|
2001-01-22 |
2004-06-29 |
Hoffmann-La Roche Inc. |
Diaminothiazoles having antiproliferative activity
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
WO2003003006A2
(fr)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
|
US20050176687A1
(en)
*
|
2001-06-29 |
2005-08-11 |
Alain Moussy |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
CA2452371A1
(fr)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de maladies allergiques
|
WO2003002108A2
(fr)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Utilisation d'inhibiteurs de tyrosine kinase destines au traitement de maladies inflammatoires
|
EP1401416B1
(fr)
*
|
2001-06-29 |
2006-10-25 |
AB Science |
Utilisation d'inhibiteurs de c-kit pour traiter les maladies intestinales inflammatoires (mii)
|
US20040266797A1
(en)
*
|
2001-06-29 |
2004-12-30 |
Alain Moussy |
Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
WO2003024386A2
(fr)
*
|
2001-09-20 |
2003-03-27 |
Ab Science |
Utilisation d'inhibiteurs c-kit puissants, selectifs et non toxiques pour le traitement de la cystopathie interstitielle sous-muqueuse
|
WO2003035050A2
(fr)
*
|
2001-09-20 |
2003-05-01 |
Ab Science |
Utilisation d'inhibiteurs de la tyrosine kinase pour stimuler la pousse des cheveux
|
WO2003026664A1
(fr)
*
|
2001-09-26 |
2003-04-03 |
Bayer Corporation |
Derives de la 2-phenylamino-4- (5-pyrazolylamino) -pyramidine, inhibiteurs de kinases et en particulier de la kinase src
|
EP1441749A4
(fr)
*
|
2001-10-25 |
2010-05-19 |
Wisconsin Alumni Res Found |
Stent ou greffon vasculaire enduit ou impregne d'inhibiteurs de tyrosine kinase, et methode d'utilisation correspondante
|
EA007298B1
(ru)
*
|
2001-11-01 |
2006-08-25 |
Янссен Фармацевтика Н.В. |
Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
GB0129476D0
(en)
*
|
2001-12-10 |
2002-01-30 |
Syngenta Participations Ag |
Organic compounds
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
EP1472245A2
(fr)
*
|
2002-02-06 |
2004-11-03 |
Vertex Pharmaceuticals Incorporated |
Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3
|
US7459455B2
(en)
|
2002-02-08 |
2008-12-02 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
CA2477111A1
(fr)
*
|
2002-02-27 |
2003-09-04 |
Ab Science |
Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de troubles du snc
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
US7442697B2
(en)
|
2002-03-09 |
2008-10-28 |
Astrazeneca Ab |
4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
EP1485381B8
(fr)
|
2002-03-15 |
2010-05-12 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
|
ATE468336T1
(de)
*
|
2002-03-15 |
2010-06-15 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
GB0206215D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
AU2003220299A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Vertex Pharmaceuticals, Inc. |
Azinylaminoazoles as inhibitors of protein kinases
|
IL165286A0
(en)
*
|
2002-06-17 |
2005-12-18 |
Smithkline Beecham Corp |
Chemical process
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
GB0215844D0
(en)
|
2002-07-09 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
MXPA05001096A
(es)
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
EP2316459B1
(fr)
*
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
Composants de 2,4-pyrimidinediamine pour être utilisés dans des procédés de traitement ou de prévention des maladies auto-immunes
|
EA200500299A1
(ru)
*
|
2002-08-02 |
2005-08-25 |
Вертекс Фармасьютикалз Инкорпорейтед |
Пиразольные композиции, используемые в качестве ингибиторов gsk-3
|
ES2422196T3
(es)
|
2002-08-09 |
2013-09-09 |
Janssen Pharmaceutica Nv |
Procesos para la preparación de 4-4-4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)aminobenzonitrilo
|
EP1562935B1
(fr)
*
|
2002-10-28 |
2006-09-06 |
Bayer HealthCare AG |
Phenylaminopyrimidine substituee par heteroaryloxy et utilisee en tant qu'inhibiteur de kinase
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
AP2385A
(en)
|
2002-12-20 |
2012-03-23 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth.
|
US20040121968A1
(en)
*
|
2002-12-23 |
2004-06-24 |
Alexander Ljubimov |
Antiangiogenesis by inhibiting protein kinase CK2 activity
|
WO2004072029A2
(fr)
*
|
2003-02-06 |
2004-08-26 |
Vertex Pharmaceuticals Incorporated |
Compositions utiles en tant qu'inhibiteurs de proteine kinases
|
JP4634367B2
(ja)
|
2003-02-20 |
2011-02-16 |
スミスクライン ビーチャム コーポレーション |
ピリミジン化合物
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
EP1644365A2
(fr)
*
|
2003-07-02 |
2006-04-12 |
Biofocus Discovery Ltd |
Composes se liant au site actif d'enzymes proteine kinases
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
JP2007500178A
(ja)
*
|
2003-07-30 |
2007-01-11 |
サイクラセル・リミテッド |
プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
|
NZ545270A
(en)
|
2003-07-30 |
2010-04-30 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
PL1660458T3
(pl)
|
2003-08-15 |
2012-07-31 |
Novartis Ag |
2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
|
GB0321710D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
AU2004278413B2
(en)
*
|
2003-09-30 |
2008-07-31 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
KR20060123164A
(ko)
|
2003-10-17 |
2006-12-01 |
아스트라제네카 아베 |
암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
|
US20050107374A1
(en)
*
|
2003-10-21 |
2005-05-19 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
MY141220A
(en)
*
|
2003-11-17 |
2010-03-31 |
Astrazeneca Ab |
Pyrazole derivatives as inhibitors of receptor tyrosine kinases
|
AU2004297235A1
(en)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
CN1906188A
(zh)
*
|
2004-01-09 |
2007-01-31 |
诺瓦提斯公司 |
作为igf-1r抑制剂的苯基-[4-(3-苯基-1h-吡唑-4-基)-嘧啶-2-基]-胺衍生物
|
BRPI0506839A
(pt)
*
|
2004-01-16 |
2007-06-12 |
Novartis Ag |
composições e métodos para induzir a cardiomiogênese
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
JP2007530453A
(ja)
*
|
2004-03-19 |
2007-11-01 |
ザ ペン ステート リサーチ ファウンデーション |
黒色腫を治療するためのコンビナトリアル法および組成物
|
US7507826B2
(en)
*
|
2004-03-30 |
2009-03-24 |
Vertex Pharmaceuticals Incorporated |
Azaindoles useful as inhibitors of JAK and other protein kinases
|
US7211576B2
(en)
|
2004-04-20 |
2007-05-01 |
Hoffmann-La Roche Inc. |
Diaminothiazoles
|
EP1751142A1
(fr)
|
2004-05-14 |
2007-02-14 |
Pfizer Products Incorporated |
Derives pyrimidiques pour le traitement de la croissance de cellules anormales
|
BRPI0511132A
(pt)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
derivados de pirimidina e composição farmacêutica compreendendo os mesmos
|
EP1758887A1
(fr)
|
2004-05-14 |
2007-03-07 |
Pfizer Products Incorporated |
Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
|
WO2005118544A2
(fr)
|
2004-05-18 |
2005-12-15 |
Rigel Pharmaceuticals, Inc. |
Composes pyrimidinediamines a substitution cycloalkyle et leurs utilisations
|
PE20060664A1
(es)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
Amidas biciclicas como inhibidores de cinasa
|
AU2005289426A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7776869B2
(en)
*
|
2004-10-18 |
2010-08-17 |
Amgen Inc. |
Heteroaryl-substituted alkyne compounds and method of use
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
CN101084214A
(zh)
|
2004-11-17 |
2007-12-05 |
迈卡纳治疗股份有限公司 |
激酶抑制剂
|
WO2006068770A1
(fr)
|
2004-11-24 |
2006-06-29 |
Rigel Pharmaceuticals, Inc. |
Composes de spiro-2, 4-pyrimidinediamine et leurs utilisations
|
EP1841760B1
(fr)
|
2004-12-30 |
2011-08-10 |
Exelixis, Inc. |
Dérivés de pyrimidine en tant que modulateurs de kinase et méthodes d'emploi
|
BRPI0606318B8
(pt)
|
2005-01-19 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, composição, e, uso de um composto
|
ATE530545T1
(de)
|
2005-02-04 |
2011-11-15 |
Astrazeneca Ab |
Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
|
ES2308731T3
(es)
|
2005-02-16 |
2008-12-01 |
Astrazeneca Ab |
Compuestos quimicos.
|
WO2006091737A1
(fr)
*
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulateurs de l'activite de gsk-3
|
ES2543607T3
(es)
|
2005-03-10 |
2015-08-20 |
Gilead Connecticut, Inc. |
Ciertas amidas sustituidas, método de obtención, y método de su uso
|
NZ564317A
(en)
|
2005-05-16 |
2011-01-28 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
WO2006129100A1
(fr)
*
|
2005-06-03 |
2006-12-07 |
Glaxo Group Limited |
Nouveaux composes
|
NZ563454A
(en)
|
2005-06-08 |
2011-03-31 |
Rigel Pharmaceuticals Inc |
2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
MX2007016066A
(es)
|
2005-07-01 |
2008-03-10 |
Irm Llc |
Derivados de bencimidazol sustituidos por pirimidina como inhibidores de cinasa de proteina.
|
WO2007028445A1
(fr)
*
|
2005-07-15 |
2007-03-15 |
Glaxo Group Limited |
Composés 6-indolyl-4-ylamino-5-halogéno-2-pyrimidinylamino
|
WO2007009681A1
(fr)
*
|
2005-07-15 |
2007-01-25 |
Glaxo Group Limited |
Derives de la 1, 1-dioxid0-2, 3-dihydro-l, 2-benzisothiaz0l-6-yl-1h-indazol-4-yl-2, 4-pyrimidine diamine
|
DE602006017574D1
(de)
|
2005-07-26 |
2010-11-25 |
Vertex Pharma |
Als protein-kinase-inhibitoren nutzbare benzimidazole
|
EP1917259B1
(fr)
*
|
2005-08-18 |
2012-01-25 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de pyrazine kinases
|
TW200738281A
(en)
|
2005-08-24 |
2007-10-16 |
Wyeth Corp |
Bazedoxifene acetate formulations
|
US7563787B2
(en)
*
|
2005-09-30 |
2009-07-21 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
KR20080049130A
(ko)
|
2005-09-30 |
2008-06-03 |
아스트라제네카 아베 |
세포 증식 억제 활성을 갖는 이미다조 [1,2-a] 피리딘
|
GB0520958D0
(en)
*
|
2005-10-14 |
2005-11-23 |
Cyclacel Ltd |
Compound
|
ES2391783T3
(es)
|
2005-10-28 |
2012-11-29 |
Astrazeneca Ab |
Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
PL1951684T3
(pl)
*
|
2005-11-01 |
2017-03-31 |
Targegen, Inc. |
Biarylowe meta-pirymidynowe inhibitory kinaz
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
WO2007056164A2
(fr)
*
|
2005-11-03 |
2007-05-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines utiles en tant qu'inhibiteurs de kinases
|
US7705009B2
(en)
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
EP2559694A3
(fr)
|
2006-01-17 |
2013-04-03 |
Vertex Pharmaceuticals, Inc. |
Azaindoles utiles en tant qu'inhibiteurs des kinases Janus
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2007085540A1
(fr)
*
|
2006-01-27 |
2007-08-02 |
Glaxo Group Limited |
Derives 1h-indaz0l-4-yl-2,4-pyrimidinediamine
|
CA2644356A1
(fr)
*
|
2006-03-16 |
2007-09-27 |
Novartis Ag |
Composes organiques
|
JP2009540013A
(ja)
*
|
2006-06-15 |
2009-11-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
2−アニリノ−4−(複素環)アミノ−ピリミジン
|
US8222256B2
(en)
|
2006-07-05 |
2012-07-17 |
Exelixis, Inc. |
Methods of using IGFIR and ABL kinase modulators
|
MX2009002229A
(es)
|
2006-09-08 |
2009-03-16 |
Hoffmann La Roche |
Benzotriazoles como moduladores de cinasas.
|
US20090054507A1
(en)
*
|
2006-09-12 |
2009-02-26 |
Cleveland State University |
Control of malignant cells by kinase inhibition
|
WO2008033308A2
(fr)
*
|
2006-09-12 |
2008-03-20 |
Cleveland State University |
Contrôle de la prolifération de cellules malignes par inhibition de la caséine kinase 2
|
JP2010509231A
(ja)
*
|
2006-11-02 |
2010-03-25 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼの阻害剤として有用なアミノピリジンおよびアミノピリミジン
|
ES2397637T3
(es)
|
2006-11-10 |
2013-03-08 |
Massachusetts Institute Of Technology |
Inhibidores de PAK para uso en el tratamiento de trastornos del desarrollo neurológico
|
KR101149295B1
(ko)
*
|
2006-12-08 |
2012-07-05 |
아이알엠 엘엘씨 |
단백질 키나제 억제제로서의 화합물
|
MX2009005508A
(es)
*
|
2006-12-08 |
2009-06-03 |
Hoffmann La Roche |
Pirimidinas substituidas y su uso como moduladores de cinasas c-jun n-terminales.
|
SI2091918T1
(sl)
|
2006-12-08 |
2015-01-30 |
Irm Llc |
Spojine in sestavki kot inhibitorji protein-kinaze
|
ATE474835T1
(de)
*
|
2006-12-19 |
2010-08-15 |
Vertex Pharma |
Als inhibitoren von proteinkinasen geeignete aminopyrimidine
|
AU2008226461A1
(en)
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines useful as inhibitors of protein kinases
|
CA2679884A1
(fr)
*
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines utiles en tant qu'inhibiteurs des proteines kinases
|
NZ579485A
(en)
*
|
2007-03-09 |
2012-02-24 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
UA98955C2
(ru)
*
|
2007-03-23 |
2012-07-10 |
Амген Инк. |
Гетероциклические соединения и их применение
|
AU2008240313A1
(en)
|
2007-04-13 |
2008-10-23 |
Aj Park |
Aminopyrimidines useful as kinase inhibitors
|
DK2154967T5
(en)
|
2007-04-16 |
2014-11-17 |
Hutchison Medipharma Entpr Ltd |
Pyriminderivater
|
AU2008247592A1
(en)
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
CN101801959A
(zh)
*
|
2007-05-02 |
2010-08-11 |
沃泰克斯药物股份有限公司 |
可用作激酶抑制剂的氨基嘧啶类化合物
|
AU2008247595A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
EP2164842A2
(fr)
*
|
2007-05-24 |
2010-03-24 |
Vertex Pharmaceuticals Incorporated |
Thiazoles et pyrazoles utiles en tant qu'inhibiteurs de kinase
|
JP2010529193A
(ja)
*
|
2007-06-11 |
2010-08-26 |
ミイカナ セラピューティクス インコーポレイテッド |
置換ピラゾール化合物
|
BRPI0814821A2
(pt)
*
|
2007-07-16 |
2015-02-03 |
Astrazeneca Ab |
Composto, composição farmacêutica, e, processo para preparar um composto
|
EP2176261B1
(fr)
|
2007-07-31 |
2012-12-19 |
Vertex Pharmaceuticals Incorporated |
Procédé de préparation de la 5-fluoro-1h-pyrazolo [3,4-b] pyridin-3-amine et des dérivés de celle-ci
|
WO2009032668A2
(fr)
|
2007-08-28 |
2009-03-12 |
Irm Llc |
Composés et compositions en tant qu'inhibiteurs de kinase
|
WO2009065132A1
(fr)
*
|
2007-11-16 |
2009-05-22 |
Oklahoma Medical Research Foundation |
Prédiction et diagnostic de patients atteints d'une maladie auto-immune
|
JP2011032169A
(ja)
*
|
2007-12-11 |
2011-02-17 |
Genecare Research Institute Co Ltd |
4−アミノピリミジン誘導体および該化合物を含有する医薬組成物
|
WO2009111644A2
(fr)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions et procédés pour diagnostiquer et traiter le cancer du pancréas
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
ES2645689T3
(es)
*
|
2008-05-21 |
2017-12-07 |
Ariad Pharmaceuticals, Inc. |
Derivados de fósforo como inhibidores de quinasas
|
AU2013205510A1
(en)
*
|
2008-05-21 |
2013-05-16 |
Ariad Pharmaceuticals, Inc. |
Phosphorous derivatives as kinase inhibitors
|
CN102076690A
(zh)
|
2008-06-23 |
2011-05-25 |
维泰克斯制药公司 |
蛋白激酶抑制剂
|
PE20100087A1
(es)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
NZ589843A
(en)
*
|
2008-06-27 |
2012-12-21 |
Avila Therapeutics Inc |
Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US8338439B2
(en)
*
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US20100016247A1
(en)
*
|
2008-07-21 |
2010-01-21 |
Florida State University Research Foundation |
Using budding yeast to screen for inhibitors of aurora kinases
|
JP2012501971A
(ja)
*
|
2008-09-03 |
2012-01-26 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
共結晶および共結晶を含む薬学的処方物
|
EP2340248B1
(fr)
*
|
2008-09-15 |
2017-05-31 |
The Regents of The University of California |
Procédés et compositions pour moduler l activité ire1, src, et abl
|
US20110178142A1
(en)
*
|
2008-10-13 |
2011-07-21 |
National Institute Of Immunology |
Pharmaceutical composition for therapeutic or prophylactic treatment of bacterial infections and associated diseases
|
TW201022262A
(en)
*
|
2008-10-29 |
2010-06-16 |
Astrazeneca Ab |
Novel compounds 515
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Egfr 억제제 및 질환 치료방법
|
CN102459265A
(zh)
*
|
2009-05-27 |
2012-05-16 |
雅培制药有限公司 |
激酶活性的嘧啶抑制剂
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
CN104922128B
(zh)
|
2009-06-17 |
2019-12-20 |
沃泰克斯药物股份有限公司 |
流感病毒复制抑制剂
|
WO2011053090A2
(fr)
*
|
2009-11-02 |
2011-05-05 |
서울대학교 산학협력단 |
Nouveaux dérivés de 2, 4-pyrimidine et utilisation
|
JP5740409B2
(ja)
|
2009-11-13 |
2015-06-24 |
ジェノスコ |
キナーゼ阻害剤
|
EP2552211A4
(fr)
*
|
2010-03-26 |
2013-10-23 |
Glaxo Group Ltd |
Indazolyl-pyrimidines utilisés en tant qu'inhibiteurs de kinase
|
JP2013523658A
(ja)
*
|
2010-03-26 |
2013-06-17 |
グラクソ グループ リミテッド |
キナーゼ阻害剤としてのピラゾリル‐ピリミジン
|
UY33549A
(es)
*
|
2010-08-10 |
2012-01-31 |
Glaxo Group Ltd |
Quinolil aminas como agentes inhibidores de las quinasas
|
DK2603081T3
(en)
|
2010-08-10 |
2017-01-16 |
Celgene Avilomics Res Inc |
COLLECTED BY A BTK INHIBITOR
|
JP5956999B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
TWI545115B
(zh)
|
2010-11-01 |
2016-08-11 |
阿維拉製藥公司 |
雜環化合物及其用途
|
CA2816957A1
(fr)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions et procedes de traitement de la myelofibrose
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
US9133224B2
(en)
|
2010-11-29 |
2015-09-15 |
OSI Pharmaceuticals, LLC |
Macrocyclic kinase inhibitors
|
CA2822057A1
(fr)
|
2010-12-16 |
2012-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de la replication des virus de la grippe
|
CA2829131C
(fr)
|
2011-03-04 |
2018-11-20 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Amino-quinoleines en tant qu'inhibiteurs de kinase
|
BR112013022697A2
(pt)
*
|
2011-03-07 |
2019-09-24 |
Fond Telethon |
inibidores de fosforilação de tfeb e usos dos mesmos
|
EA201391626A1
(ru)
|
2011-05-04 |
2014-03-31 |
Ариад Фармасьютикалз, Инк. |
Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
|
AU2012279046B2
(en)
|
2011-07-05 |
2017-08-31 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates for producing azaindoles
|
US8673269B2
(en)
|
2011-07-14 |
2014-03-18 |
Keith R. Latham |
Halogenated phenols for diagnostics, antioxidant protection and drug delivery
|
ES2834093T3
(es)
|
2011-07-21 |
2021-06-16 |
Sumitomo Dainippon Pharma Oncology Inc |
Inhibidores de proteína quinasa heterocíclicos
|
UA118010C2
(uk)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
Інгібітори реплікації вірусів грипу
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
EP2754659A4
(fr)
*
|
2011-09-05 |
2015-08-26 |
Zhejiang Hisun Pharm Co Ltd |
Dérivés 4-substitué-(3-substitué-1h-pyrazole-5-amino)-pyrimidines ayant une activité d'inhibition de protéine kinase et son utilisation
|
MX342326B
(es)
*
|
2011-09-27 |
2016-09-26 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
|
EP2770830A4
(fr)
|
2011-10-28 |
2015-05-27 |
Celgene Avilomics Res Inc |
Méthodes de traitement d'une maladie ou d'une affection associée à la tyrosine-kinase btk (bruton's tyrosine kinase)
|
KR101401664B1
(ko)
*
|
2011-11-15 |
2014-06-11 |
중앙대학교 산학협력단 |
신경줄기세포 분화조절제용 신규 피리미딘-2,4-디아민 유도체 및 이의 의학적 용도
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
EP2825041B1
(fr)
|
2012-03-15 |
2021-04-21 |
Celgene CAR LLC |
Formes solides d'un inhibiteur de kinases du récepteur du facteur de croissance épidermique
|
ES2698298T3
(es)
|
2012-03-15 |
2019-02-04 |
Celgene Car Llc |
Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
|
AU2013204563B2
(en)
|
2012-05-05 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
EP2863913B1
(fr)
*
|
2012-06-20 |
2018-09-12 |
Merck Sharp & Dohme Corp. |
Analogues d'imidazolyle en tant qu'inhibiteurs de syk
|
WO2013192125A1
(fr)
|
2012-06-20 |
2013-12-27 |
Merck Sharp & Dohme Corp. |
Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
|
TW201425307A
(zh)
|
2012-09-13 |
2014-07-01 |
Glaxosmithkline Llc |
作為激酶抑制劑之胺基-喹啉類
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
CN104884452A
(zh)
|
2012-11-20 |
2015-09-02 |
沃泰克斯药物股份有限公司 |
用作吲哚胺2,3-二氧化酶的抑制剂的化合物
|
EP2922828B1
(fr)
*
|
2012-11-21 |
2020-07-08 |
PTC Therapeutics, Inc. |
Dérivés de 4,6-diamino-pyrimidine en tant qu'inhibiteurs bmi-1 pour le traitement du cancer
|
US9512136B2
(en)
*
|
2012-11-26 |
2016-12-06 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
EP2935226A4
(fr)
|
2012-12-21 |
2016-11-02 |
Celgene Avilomics Res Inc |
Composés hétéroarylés et leurs utilisations
|
CA2900012A1
(fr)
|
2013-02-08 |
2014-08-14 |
Celgene Avilomics Research, Inc. |
Inhibiteurs d'erk et leurs utilisations
|
CN105143208B
(zh)
|
2013-02-21 |
2017-09-26 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为激酶抑制剂的喹唑啉
|
US10202356B2
(en)
*
|
2013-03-14 |
2019-02-12 |
Tolero Pharmaceuticals, Inc. |
JAK2 and ALK2 inhibitors and methods for their use
|
MX2015012822A
(es)
*
|
2013-03-14 |
2016-05-31 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
|
JP6387360B2
(ja)
|
2013-03-14 |
2018-09-05 |
ノバルティス アーゲー |
変異idhの阻害薬としての3−ピリミジン−4−イル−オキサゾリジン−2−オン
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
WO2014181813A1
(fr)
*
|
2013-05-10 |
2014-11-13 |
武田薬品工業株式会社 |
Composé hétérocyclique
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
WO2015030847A1
(fr)
|
2013-08-30 |
2015-03-05 |
Ptc Therapeutics, Inc. |
Inhibiteurs de bmi-1 à base de pyrimidines substituées
|
SI3068782T1
(sl)
|
2013-11-13 |
2018-10-30 |
Vertex Pharmaceuticals Incorporated |
Postopki za pripravo inhibitorjev v replikacije virusov gripe
|
SI3068776T1
(sl)
|
2013-11-13 |
2019-09-30 |
Vertex Pharmaceuticals Incorporated |
Inhibitorji replikacije virusov influence
|
EP3071553A4
(fr)
|
2013-11-21 |
2017-08-02 |
PTC Therapeutics, Inc. |
Inhibiteurs de bmi-1 à base de pyridine et de pyrazine substituées
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
EP3179858B1
(fr)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Formes et compositions d'un inhibiteur d'erk
|
EP3929190A1
(fr)
*
|
2014-10-13 |
2021-12-29 |
Yuhan Corporation |
Composés et compositions de modulation des activités de kinase mutant egfr
|
CN105085489B
(zh)
|
2014-11-05 |
2019-03-01 |
益方生物科技(上海)有限公司 |
嘧啶或吡啶类化合物、其制备方法和医药用途
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
CN113350353A
(zh)
*
|
2015-03-23 |
2021-09-07 |
墨尔本大学 |
呼吸性疾病的治疗
|
WO2016183116A1
(fr)
|
2015-05-13 |
2016-11-17 |
Vertex Pharmaceuticals Incorporated |
Procédés de préparation d'inhibiteurs de réplication des virus de la grippe
|
JP6857617B2
(ja)
|
2015-05-13 |
2021-04-14 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
インフルエンザウイルスの複製の阻害剤
|
JP6970081B2
(ja)
*
|
2015-07-16 |
2021-11-24 |
正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 |
アニリンピリミジン誘導体及びその使用
|
CN105061506B
(zh)
*
|
2015-07-27 |
2017-08-29 |
苏州明锐医药科技有限公司 |
抗肿瘤药物ap26113的制备方法
|
SG11201803653QA
(en)
|
2015-11-02 |
2018-05-30 |
Blueprint Medicines Corp |
Inhibitors of ret
|
CN106699810A
(zh)
*
|
2015-11-17 |
2017-05-24 |
清华大学 |
一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
|
KR20180098679A
(ko)
|
2016-01-22 |
2018-09-04 |
잔센파마슈티카엔.브이. |
Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
|
EP3405196B1
(fr)
|
2016-01-22 |
2019-12-04 |
Janssen Pharmaceutica NV |
Nouveaux dérivés de cyanoindoline n-phenylpyrimidin-2-amine substitués en tant qu'inhibiteurs de nik
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
TW201738228A
(zh)
|
2016-03-17 |
2017-11-01 |
藍圖醫藥公司 |
Ret之抑制劑
|
WO2018002219A1
(fr)
|
2016-06-30 |
2018-01-04 |
Janssen Pharmaceutica Nv |
Nouveaux dérivés de cyanoindoline comme inhibiteurs de nik
|
WO2018002217A1
(fr)
|
2016-06-30 |
2018-01-04 |
Janssen Pharmaceutica Nv |
Dérivés hétéroaromatiques en tant qu'inhibiteurs de nik
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
WO2018022761A1
(fr)
|
2016-07-27 |
2018-02-01 |
Blueprint Medicines Corporation |
Cyclopentane-amides substitués pour le traitement des troubles liés au ret
|
US11149032B2
(en)
*
|
2016-12-19 |
2021-10-19 |
Isocure Biosciences Inc. |
Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
|
CA3096043A1
(fr)
|
2018-04-03 |
2019-10-10 |
Blueprint Medicines Corporation |
Inhibiteur de ret destine a etre utilise dans le traitement du cancer presentant une alteration du ret
|
CA3096984A1
(fr)
|
2018-04-05 |
2019-10-10 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Inhibiteurs de kinases axl et leur utilisation
|
KR20200143454A
(ko)
|
2018-04-13 |
2020-12-23 |
스미토모 다이니폰 파마 온콜로지, 인크. |
골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제
|
CN108864052A
(zh)
*
|
2018-06-07 |
2018-11-23 |
福建医科大学 |
一种针对gc33-3-1抗体具有特异性识别的荧光探针的合成以及应用
|
JP2021530554A
(ja)
|
2018-07-26 |
2021-11-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
MX2021009371A
(es)
|
2019-02-12 |
2021-09-10 |
Sumitomo Pharma Oncology Inc |
Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
|
WO2020168197A1
(fr)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
WO2020223558A1
(fr)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Composés aminés tricycliques en tant qu'inhibiteurs de cdk2
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
AR119765A1
(es)
|
2019-08-14 |
2022-01-12 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
|
CN110746402B
(zh)
*
|
2019-09-21 |
2021-01-15 |
温州医科大学 |
一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用
|
CN110669038B
(zh)
*
|
2019-09-21 |
2020-10-30 |
温州医科大学 |
一种嘧啶类fgfr4v550l抑制剂及其制备方法和应用
|
WO2021072232A1
(fr)
|
2019-10-11 |
2021-04-15 |
Incyte Corporation |
Amines bicycliques utilisées en tant qu'inhibiteurs de cdk2
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
WO2024097653A1
(fr)
|
2022-10-31 |
2024-05-10 |
Sumitomo Pharma America, Inc. |
Inhibiteur de pim-1 pour le traitement de néoplasmes myéloprolifératifs
|